Skip to main content
. 2019 Jun;11(6):2458–2469. doi: 10.21037/jtd.2019.05.81

Figure 5.

Figure 5

Kaplan-Meier survival analysis of risk factors in stage IV lung cancer patients involved in this study. (A) the overall survival analysis based on pre-therapeutic mSHOX2 level with stratifying threshold at the ΔΔCt median of −1.62; (B) the overall survival analysis based on two cycles post-therapeutic mSHOX2 level with stratifying threshold at the ΔΔCt median of −4.0; (C) the overall survival analysis based on mSHOX2 level change (ΔΔCt change) with stratifying threshold at the median of −2.72; (D) the overall survival analysis based on targeted tumor maximal diameter change with stratifying threshold at the median of 31.6%.